Pfizer posts Phase 3 Elrexfio win in relapsed myeloma: full analysis

Pfizer has reported a potentially practice-shaping win for Elrexfio, saying the Phase 3 MagnetisMM-5 trial significantly improved progression-free survival in adults with relapsed or refractory multiple myeloma compared with daratumumab, pomalidomide, and dexamethasone. The topline result, announced April 29, 2026, gives Pfizer its clearest late-stage evidence yet that elranatamab may have a role earlier in treatment, beyond the heavily pretreated setting covered by its current U.S. approval. (pfizer.com)

That matters because Elrexfio entered the U.S. market in 2023 under accelerated approval for adults with relapsed or refractory multiple myeloma after at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. The FDA label still states that continued approval may depend on confirmatory evidence of clinical benefit. MagnetisMM-5 has long been one of the key studies to watch because it tests whether Pfizer can translate earlier single-arm activity into randomized Phase 3 benefit. (pfizer.com)

According to Pfizer, MagnetisMM-5 evaluated Elrexfio monotherapy in adults with relapsed or refractory multiple myeloma who had received at least one prior line of treatment. At an interim analysis, the study met its primary endpoint, with blinded independent central review showing a statistically significant and clinically meaningful progression-free survival advantage over the comparator regimen of daratumumab plus pomalidomide and dexamethasone. Pfizer also said the result exceeded the pre-specified interim hazard ratio target for efficacy, while most Elrexfio-treated patients remained progression-free at the time of analysis. Overall survival, a key secondary endpoint, was not yet mature. (pfizer.com)

The result builds on the drug’s earlier development program. In the pivotal MagnetisMM-3 study that supported approval, elranatamab produced a 61.0% overall response rate in BCMA-naive relapsed or refractory multiple myeloma, with complete or stringent complete responses in 37.4% of patients, according to a recent peer-reviewed review summarizing the program. But MagnetisMM-3 was single-arm, which limited interpretation against standard regimens and left confirmatory work unfinished. ClinicalTrials.gov lists MagnetisMM-5 as a study designed to compare elranatamab-based treatment with established therapy in previously treated multiple myeloma, underscoring its importance in the regulatory path. (pubmed.ncbi.nlm.nih.gov)

Pfizer has not yet released the full efficacy tables, subgroup analyses, or detailed adverse-event breakdown from MagnetisMM-5, so outside commentary has been limited so far. Still, the company said no new safety signals emerged, which will be closely scrutinized given the class’s known toxicities. The current U.S. prescribing information carries boxed warnings for cytokine release syndrome and neurologic toxicity, including ICANS, and notes a REMS program as well as common risks including infections, cytopenias, and pneumonia. (pfizer.com)

Why it matters: For clinicians, pharmacists, infusion teams, and health-system administrators, the significance goes beyond one positive readout. A successful confirmatory study could help secure Elrexfio’s place in the market and potentially move a BCMA-directed bispecific into earlier lines of therapy, where treatment sequencing becomes more competitive and operationally complex. Earlier-line use could affect how teams think about sequencing against CAR-T therapies, other bispecifics, anti-CD38 combinations, and future BCMA- or GPRC5D-directed options. That said, the topline nature of the release means it’s still too early to know which patient subgroups benefited most, how tolerability compares in routine practice, or whether overall survival will ultimately strengthen the case. Those are reasonable inferences based on the trial design and current label, rather than conclusions Pfizer has fully published. (pfizer.com)

For veterinary professionals reading broadly across biopharma, this is also a reminder of how confirmatory oncology trials shape commercial durability. Accelerated approvals can open access early, but randomized data remain central to long-term regulatory and market positioning. The Elrexfio story now shifts from proof of concept to proof of staying power, with implications for prescribing confidence, payer discussions, and competitive pressure across the multiple myeloma pipeline. (accessdata.fda.gov)

What to watch: Pfizer said it will discuss the data with global health authorities and present detailed results at a future medical congress. The next milestones are likely to include a full data presentation with hazard ratios and safety tables, potential regulatory submissions for broader use, and later overall survival readouts that will help determine whether MagnetisMM-5 changes the label, the treatment algorithm, or both. (pfizer.com)